NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of John M. Goldberg, MD as fractional Chief Medical Officer (CMO) to advance development of its Large Surface Area ...
Hesperos is a global contract research organization (CRO) specializing in preclinical drug development services utilizing its Human-on-a-Chip ® platform. By replicating key aspects of human biology ...
Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...
TORONTO--(BUSINESS WIRE)--Conscience, a non-profit focused on accelerating drug discovery in areas of unmet medical need using open science and radical collaboration, is pleased to announce three ...
Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a ...
Xellar Biosystems ("Xellar"), a globally leading innovator in next-generation artificial intelligence- and computer vision–assisted, organ-on-a-chip–based drug discovery and development platforms, ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 ...
Polyrizon Ltd., a biotechnology company focused on intranasal drug delivery systems, has reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, developed in ...
The liver is accountable for metabolizing most medications and is therefore one of the primary tissues affected by adverse drug reactions. Most classes of medicine can cause drug-induced liver injury ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback